Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2020

View Archived Issues

Brown fat activity without fat browning

FDA lifts hold and clears IND application for IMS-001

Agonists selectively wake up melatonin receptor subtypes

IND application for AG-946 cleared by FDA

Enhancing TREM2's protective function on microglia as a novel approach for Alzheimer's disease

Ciclesonide shows antiviral activity against SARS-CoV-2

First patients enrolled in RECOVERY study evaluating potential COVID-19 treatments

Vaccitech presents initial data from phase IIa ADVANCE study of VTP-800

miR-423-5p and miR-128-3p in serum exosome as biomarkers for testicular injury

Novel lipid biomarkers for ETH-induced hepatic steatosis

Elevated AXIN1 expression as predictor of PTSD development

TNFSF14 is a therapeutic target in eosinophilic esophagitis

Biomarkers predict renal recovery from acute kidney injury requiring dialysis

Nanocells deliver cytotoxin, activate immune system

Roche and Genentech patent TEAD inhibitors

Novartis divulges new compounds for herpesvirus infection

H. Lee Moffitt Cancer Center and Research Institute presents BRD4-JAK2 inhibitors

Otsuka Pharmaceutical identifies AhR antagonists

New AMPK activators presented by Skylark Bioscience

Ascletis publishes data from clinical study of danoprevir for COVID-19

Novartis' Beovu approved in Japan for neovascular age-related macular degeneration

Japanese approval of Tepmetko for advanced NSCLC with METex14 skipping alterations

Phase I results with losmapimod for FSHD show target engagement in muscle

Antolimab begins new trials, shows promise for mast cell gastrointestinal disease

BeiGene studies BGB-11417 in phase I for mature B-cell malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...